Fulcrum Therapeutics, INC Schedule 13G passive stakes

RA Capital Management, L.P. and related entities have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Fulcrum Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 5,475,040 shares, representing 8.22% of Fulcrum Therapeutics, Inc.'s common stock as of June 30, 2026.

Montanova Capital, Averill Master Fund, and Aaron Cowen have collectively increased their beneficial ownership in Fulcrum Therapeutics to 5.5% and 3.8% respectively, as of June 30, 2026.

TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC, along with Chen Yu, have filed an amendment to their Schedule 13G for Fulcrum Therapeutics, Inc., reporting no change in beneficial ownership.

Bank of America Corp /DE/ has reported beneficial ownership of 4,468,123 shares, representing 6.7% of the common stock of Fulcrum Therapeutics, Inc.

Tang Capital Management and affiliated entities have reported beneficial ownership of 10.4% of Fulcrum Therapeutics, Inc. common stock.

EcoR1 Capital, LLC and Oleg Nodelman have reported a 9% beneficial ownership stake in Fulcrum Therapeutics, Inc. via a Schedule 13G filing.

EcoR1 Capital, LLC and Oleg Nodelman have reported a 9% beneficial ownership stake in Fulcrum Therapeutics, Inc. via a Schedule 13G filing.

Tang Capital Management and Kevin Tang have reported an 8.2% beneficial ownership stake in Fulcrum Therapeutics, Inc. via a Schedule 13G filing.

Nantahala Capital Management, LLC and its principals have reported a 4.58% beneficial ownership stake in Fulcrum Therapeutics, Inc. as of March 31, 2026.

TCG Crossover Fund II, L.P. and associated entities have reported a 7.9% beneficial ownership stake in Fulcrum Therapeutics, Inc.

The Vanguard Group has reported a 0% beneficial ownership in Fulcrum Therapeutics Inc. following an internal realignment.

RA Capital Management and its affiliates reported a continued 11.2% beneficial ownership stake in Fulcrum Therapeutics, holding 6,053,960 common shares.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 4.5% beneficial ownership stake in Fulcrum Therapeutics, Inc. as of September 30, 2025.

BlackRock, Inc. has increased its beneficial ownership in Fulcrum Therapeutics Inc. to 6.0% of the common stock, holding 3,270,322 shares.

Adage Capital Management, L.P. and its principals have disclosed a beneficial ownership of 8.5% in Fulcrum Therapeutics, Inc. common stock.

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen have filed an amended Schedule 13G, disclosing their beneficial ownership of 9.4% and 8.6% respectively, in Fulcrum Therapeutics, Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 7.5% of the common stock of Fulcrum Therapeutics Inc. as of March 31, 2025.

Adage Capital Management, L.P., along with its principals Robert Atchinson and Phillip Gross, has reported a 5.56% beneficial ownership stake in Fulcrum Therapeutics, Inc. as of December 31, 2024.

Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd. and Aaron Cowen, has disclosed a significant passive ownership stake of 6.3% in Fulcrum Therapeutics, Inc. common stock.